{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:32:01Z","timestamp":1770388321416,"version":"3.49.0"},"reference-count":31,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2023,9]]},"abstract":"\n BACKGROUND:<\/jats:title>\n Hepatitis C virus (HCV) can cause chronic liver disease, hepatic cirrhosis, hepatocellular carcinoma, liver transplantation, and death. Early diagnosis and treatment are thus vital.<\/jats:p>\n <\/jats:sec>\n \n OBJECTIVES:<\/jats:title>\n We aimed to investigate the sustained virological response (SVR) rates in chronic hepatitis C patients infected with different genotypes, receiving different direct-acting antiviral treatments (DAAs).<\/jats:p>\n <\/jats:sec>\n \n DESIGN:<\/jats:title>\n Retrospective, observational<\/jats:p>\n <\/jats:sec>\n \n SETTING:<\/jats:title>\n Clinic for infectious diseases and clinical microbiology<\/jats:p>\n <\/jats:sec>\n \n PATIENTS AND METHODS:<\/jats:title>\n Patients diagnosed with chronic hepatitis C who applied to our outpatient clinic between January 2016 and November 2022 and were treated with a DAA were included in the study. Treatment responses were evaluated after each patient was treated with either ledipasvir plus sofosbuvir (LDV\/SOF), LDV\/SOF + ribavirin (RBV), SOF+RBV, ombitasvir\/paritaprevir\/ritonavir plus dasabuvir (OBV\/PTV\/r\u00b1DSV) \u00b1RBV, or glecaprevir plus pibrentasvir (GLE\/PIB).<\/jats:p>\n <\/jats:sec>\n \n MAIN OUTCOME MEASURES:<\/jats:title>\n Sustained virological response (SVR) rates at 12 weeks (SVR12) post-treatment.<\/jats:p>\n <\/jats:sec>\n \n SAMPLE SIZE:<\/jats:title>\n 360 patients.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n \n Of 360 patients who met the inclusion criteria, 218 (60.6%) were male and 142 (39.4%) were female with no statistically significant differences in SVR between sexes (\n P<\/jats:italic>\n =.252). Nearly all had a SVR (n=353, 98.1%). The median (IQR) age of the patients was 56 (30.3) years. There were 42 (11.7%), 199 (55.3%), 4 (1.1%), 106 (29.4%), 8 (2.2%) and 1 (0.3%) patient with genotypes 1a, 1b, 2, 3, 4 and 5, respectively, and SVR12 did not differ significantly between genotypes (\n P<\/jats:italic>\n =.066). SVR12 response was higher in 246 (68.3%) non-injecting drug users compared to 114 (31.7%) injecting drug users (\n P<\/jats:italic>\n =.005). The SVR12 response was achieved in 100% of patients with genotypes 1a, 2, 4, and 5. SVR12 response could not be obtained in 1 of 199 genotype 1b patients and 6 of 106 genotype 3 patients. The common feature of 6 reinfection patients with genotype 3 was that they were using intravenous drugs. These 6 patients were reinfected due to their continued intravenous drug use.\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n In conclusion, DAAs provide high SVR12 rates in cirrhotic\/non-cirrhotic, pegylated interferon-naive\/experienced patient groups and in patients infected with all genotypes. DAAs have a high SVR12 rate in patients with chronic hepatitis C.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS:<\/jats:title>\n Retrospective, single-center.<\/jats:p>\n <\/jats:sec>","DOI":"10.5144\/0256-4947.2023.308","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T08:58:48Z","timestamp":1696841928000},"page":"308-314","source":"Crossref","is-referenced-by-count":3,"title":["Experience with direct-acting antivirals in genotype 1\u20135 infected chronic hepatitis C patients in Turkey"],"prefix":"10.5144","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8293","authenticated-orcid":false,"given":"Ahmet","family":"Sahin","sequence":"first","affiliation":[{"name":"From the Department of Infectious Diseases and Clinical Microbiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Akay","sequence":"additional","affiliation":[{"name":"From the Department of Biostatistics, Gaziantep Islam Science and Technology University, Gaziantep, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00472-6"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.028"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010095"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1921737"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(17)30496-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13080"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Bal T Cabalak M. Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. 2020.","DOI":"10.5455\/annalsmedres.2020.04.413"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.09.002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315906"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2020.19569"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000001166"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000533"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2022.102388"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckr083"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20200811-000449"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58030436"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa377"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00519-y"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.455"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01780.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000021972"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(19)30417-0"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.458"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i18.2229"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa006"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:04:40Z","timestamp":1696849480000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2023.308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.5144\/0256-4947.2023.308"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2023.308","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}